



(11) **EP 2 741 605 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
17.06.2020 Bulletin 2020/25

(51) Int Cl.:
A01N 1/02 (2006.01) **A61K 35/14** (2015.01)
B01D 15/00 (2006.01) **B01J 20/00** (2006.01)

(21) Application number: **12824141.1**

(86) International application number:
PCT/US2012/050295

(22) Date of filing: **10.08.2012**

(87) International publication number:
WO 2013/025483 (21.02.2013 Gazette 2013/08)

(54) **POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS**

POLYMERES SORPTIONSMITTEL ZUR ENTFERNUNG VON VERUNREINIGUNGEN AUS
VOLLBLUT UND BLUTPRODUKTEN

SORBANT POLYMÈRE POUR L'ÉLIMINATION D'IMPURETÉS À PARTIR DU SANG TOTAL ET DES
PRODUITS SANGUINS

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **CAPPONI, Vincent, J.**
Monmouth Junction, NJ 08852 (US)
- **GOLOBISH, Thomas, D.**
Princeton, NJ 08540 (US)
- **ALI, Humayra, Begum**
Princeton, NJ 08540 (US)

(30) Priority: **12.08.2011 US 201161523170 P**

(43) Date of publication of application:
18.06.2014 Bulletin 2014/25

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

(73) Proprietor: **Cytosorbents Corporation**
Monmouth Junction, NJ 08852 (US)

(56) References cited:
WO-A1-2009/158027 WO-A1-2012/094565
DE-A1- 10 157 569 US-A- 6 162 469
US-A1- 2008 119 576

(72) Inventors:
• **CHAN, Phillip, P.**
Cherry Hill, NJ 08003 (US)

EP 2 741 605 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**TECHNICAL FIELD**

5 **[0001]** The present invention concerns compositions and methods useful in the removal of cytokines, bioactive lipids, free hemoglobin, membrane or cellular degradation products, inflammatory mediators, vasoactive substances, foreign antigens, and antibodies from blood and blood products.

BACKGROUND

10 **[0002]** The transfusion of whole blood or derivatives of whole blood ("blood products") are literally the lifeblood of patients with a range of conditions from severe trauma to surgery to cancer. According to the American Red Cross, there are more than 14 million packed red blood cell (pRBC) transfusions per year in the United States with 1 in every ten admissions to US hospitals requiring a blood transfusion on average. A similar number of transfusions of other fractions of whole blood, or blood products, such as platelets, white blood cells, plasma, albumin, immunoglobulins, clotting factors and cryoprecipitate, are administered each year. The critical need for blood extends to the military, where logistics of blood transport and storage are complicated and 8% of all hospital admissions during Operation Iraqi Freedom required massive transfusions, defined as more than 10 units of blood in the first 24 hours. Whole blood and blood products will be collectively referred to herein as "blood".

20 **[0003]** Blood has a limited life span. A typical pRBC unit has a usable life of only 42 days while platelets must be used within 5 days of donation. This, coupled with the high demand for blood, has led to periodic blood shortages. But many medical experts believe fresh blood should be used even sooner, within 2-4 weeks. Retrospective studies have implicated transfusions of "older" blood with an increased risk of non-hemolytic transfusion reactions such as fever, transfusion related acute lung injury (TRALI), transfusion associated dyspnea (TAD), allergic reactions, infection, death and other complications. In one of these studies, the risk of in-hospital death increased by 2% for each day a packed red cell unit aged. Because of this, extending the useful life of blood products and improving the quality of blood would be helpful. WO2012/094565 A1 discloses methods of treating blood, blood products or physiologic fluid to maximize shelf life and/or minimize transfusion related complications. WO2009/158027 A1 discloses a polymer sorbent which clears myoglobin from blood and/or other physiological fluids and solutions. US2008/119576 A1 discloses size-selective hemocompatible porous polymeric adsorbents with a pore structure capable of excluding molecules larger than 50,000 Daltons, but with a pore system that allows good ingress and egress of molecules smaller than 35,000 Daltons. DE 101 57 569 A1 discloses a process for the purification of blood, in which non-cellular blood components of a patient are separated by known separation processes and then supplied for further purification.

SUMMARY

35 **[0004]** In one embodiment of the invention, transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion related acute lung injury (TRALI), transfusion associated dyspnea (TAD), allergic reactions are mitigated by removing undesirable molecules from blood through use of a sorbent. Use of a sorbent to remove undesirable products from transfusable blood can also extend the useful shelf life of this blood by, for example, removing undesirable products that accumulate during storage. These undesirable products found in blood are herein collectively referred to as Biologically Active Molecules (BAM)s. BAMs are defined as any substance or molecule that can, by itself or in combination with other BAMs, cause a biological, cellular or physiologic process. During blood transfusions, BAMs can elicit an undesirable physiologic response in the recipient of the transfused blood, such as TRALI, TAD, and others. For example, anti-human leukocyte antigen antibodies are BAMs linked to severe cases of TRALI. Prions, another example of a BAM, can cause Creutzfeldt-Jakob disease or subacute spongiform encephalopathy. A subset of BAMs are biological response modifiers (BRMs), which are substances that have an effect on the immune system. These include, for example, cytokines, chemokines, antibodies, glycoproteins, and growth factors. Cytokines found in transfusable blood can cause fever in the recipient.

40 **[0005]** In another embodiment, BAMs present in blood and blood products such as drugs, inflammatory mediators and stimulators such as cytokines, chemokines, interferons, nitric oxide, thromboxanes, leukotrienes, platelet-activating factor, prostaglandins, glycoproteins, kinins, kininogens, complement factors, cell-adhesion molecules, superantigens, monokines, free radicals, proteases, arachidonic acid metabolites, prostacyclins, beta endorphins, myocardial depressant factors, anandimide, 2-arachadonylglycerol, tetrahydrobiopterin, histamine, bradykinin, soluble CD40 ligand, serotonin, hemoglobin, bioactive lipids, antibodies, antigens, prions, toxins, endotoxins, membrane or cellular components, and other BRMs are removed by the sorbent. These BAMs may have been present in the donor's blood at the time the blood donation was made or may develop over time as the blood is processed, or is in storage, or as part of the aging process.

[0006] Suitable sorbents include biocompatible polymers. Certain polymers are hemocompatible. Some biocompatible polymers are supplied as a slurry, or suspension, or dry powder or other dry particulate capable of being wetted.

[0007] In some embodiments, a blood storage bag or suitable blood container may be used such that the polymeric sorbents are in the form of beads, such that the beads are neutrally buoyant in blood. Suitable buoyant beads of polymeric sorbents will have a density that is comparable to the composition (fluid) in which the beads reside.

[0008] In another embodiment, sorbents are neutrally buoyant in blood so that BAMs can be removed throughout the whole volume of blood without the need for mixing over time.

[0009] In some embodiments, the donated blood is treated with a sorbent to remove undesirable antibodies such as anti-leukocyte antibodies, and anti-human leukocyte antigen antibodies, at the time of donation, during storage, or at the point of use.

[0010] In another embodiment, increasing the apparent density of the beads by adding heavier heteroatoms to the polymer matrix allows the synthesis of neutrally buoyant beads in relation to Packed Red Blood Cells (RBC's). This can be accomplished by suspension, seed, dispersion, precipitation, multistage, membrane/microchannel emulsification and microfluidic polymerizations to form neutrally buoyant porous particles (Gokmen MT, Du Prez FE. Porous polymer particles-A comprehensive guide to synthesis, characterization, functionalization and applications. Prog Polym Sci 2012;37:365-405).

[0011] In other embodiments, polymers comprise particles having a diameter in the range for 0.1 micron meters to 2 centimeters. Certain polymers are in the form of powder, beads or other regular or irregularly shaped particulates.

[0012] In certain embodiments, the polymer is made of particles having a diameter in the range for 0.1 micron meters to 2 centimeters, is porous, and has a pore structure that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry polymer.

[0013] The polymer of the invention is a copolymer of divinylbenzene and 4-chlorostyrene. Some polymers of the disclosure comprise residues from one or more monomers or heteroatom containing monomers or mixtures thereof selected from divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinyl-naphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, 2-chlorostyrene, 3-chlorostyrene, 4-chlorostyrene, 2,6-dichlorostyrene, 4-vinylbenzyl chloride, 2-bromostyrene, 3-bromostyrene, 4-bromostyrene, 2-fluorostyrene, 3-fluorostyrene, 4-fluorostyrene, 2-trifluoromethylstyrene, 3-trifluoromethylstyrene, 4-trifluoromethylstyrene, 2,3,4,5,6-pentafluorostyrene, 4-vinyl-18-crown-6 benzene, 2-chloroacrylate, 2,2,2-trifluoromethylmethacrylate, 2-trifluoromethylacrylate, methyl 2-(chloromethyl)acrylate, methyl 2-(bromomethyl)acrylate, 1H, 1H, 2H, 2H-heptadecafluorodecyl acrylate, vinyl chloroacetate, and 2-chloroethyl vinyl ether.

[0014] In some embodiments, the polymer is a coated polymer comprising at least one crosslinking agent and at least one dispersing agent. The dispersing agent may be hemocompatible. The dispersing agents can be selected from chemicals, compounds or materials such as hydroxyethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), and salts of poly(acrylic acid) and mixtures thereof; the crosslinking agent selected from a group consisting of divinylbenzene, trivinylbenzene, divinyl-naphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylates, pentaerythritol trimethacrylates, pentaerythritol tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, divinylformamide and mixtures thereof. Preferably, the polymer is developed simultaneously with the formation of the coating, wherein the dispersing agent is chemically bound to the surface of the polymer.

[0015] Some embodiments of the invention use an organic solvent and/or polymeric porogen as the porogen or pore-former, and the resulting phase separation induced during polymerization yield porous polymers. Some preferred porogens are benzyl alcohol, cyclohexane, cyclohexanol, cyclohexanol/toluene mixtures, cyclohexanone, decane, decane/toluene mixtures, di-2-ethylhexylphosphoric acid, di-2-ethylhexyl phthalate, 2-ethyl-1-hexanoic acid, 2-ethyl-1-hexanol, 2-ethyl-1-hexanol/n-heptane mixtures, 2-ethyl-1-hexanol/toluene mixtures, isoamyl alcohol, n-heptane, n-heptane/ethylacetate, n-heptane/isoamyl acetate, n-heptane/tetraline mixtures, n-heptane/toluene mixtures, n-hexane/toluene mixtures, pentanol, poly(styrene-co-methyl methacrylate)/dibutyl phthalate, polystyrene/2-ethyl-1-hexanol mixtures, polystyrene/dibutyl phthalate, polystyrene/n-hexane mixtures, polystyrene/toluene mixtures, toluene, tri-n-butyl-

phosphate, 1,2,3-trichloropropane/2-ethyl-1-hexanol mixtures, 2,2,4-trimethyl pentane (isooctane), trimethyl pentane/toluene mixtures, poly(propylene glycol)/toluene mixtures poly(propylene glycol)/cyclohexanol mixtures, and poly(propylene glycol)/2-ethyl-1-hexanol mixtures

[0016] In one embodiment, the polymer is capable of sorbing protein molecules approximately 100 Daltons to about 1,000 Kilodaltons.

[0017] In another embodiment a porous polymer that sorbs small to midsize protein molecules equal to or less than 50,000 Daltons and excludes or reduces absorption of large blood proteins comprises the pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å are in the range of 0.5 cc/g to 5.0 cc/g dry sorbent. The sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 100 Å to 1,000 Å (pore diameter) of the sorbent is smaller than 3:1.

[0018] In another embodiment a porous polymer that optimally sorbs midsize to large size protein molecules of approximately 300,000 Daltons and excludes or reduces absorption of very large blood proteins comprises the pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å are in the range of 0.5 cc/g to 5.0 cc/g dry sorbent. The sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1

[0019] In another embodiment a porous polymer that optimally sorbs very large size protein molecules equal to or less than 1,000,000 Daltons (100 Daltons to 450,000 Daltons in some embodiments) and excludes or reduces absorption of very large blood proteins comprises the pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å are in the range of 0.5 cc/g to 5.0 cc/g dry sorbent. The sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 10,000 Å to 40,000 Å (pore diameter) of the sorbent is smaller than 3:1.

[0020] In some embodiments, the polymers may be derivatized. Some polymers may be modified with an antibody or ligand. Certain ligands specifically or non-specifically bind reactive biomolecules. Such polymer may be porous or solid.

[0021] In some embodiments, the composition is contained in a suitable blood container with the blood or blood products. In certain embodiments, the invention concerns a blood storage bag comprising any of the compositions discussed herein. In some embodiments, the sorbent is in a suitable container to hold blood and in direct contact with blood and blood products but incapable of escaping from the container. In some embodiments the composition is part of the storage container material that forms the container. In some embodiments, the composition is coated or deposited on the interior surface of the storage container and in direct contact with blood or blood products. In some embodiments the material is separated from the blood via membrane but fluid may pass through the membrane allowing BRMs to communicate with the composition but excluding cells such as white blood cells, red blood cells and platelets. Some methods further comprise separating the composition from the blood via filtration. In certain embodiments the filtration occurs while the blood is removed from the storage bag during transfusion to a patient. In some embodiments the sorbent in the blood container is in direct contact with the blood.

[0022] In other embodiments, the sorbent is structurally an integral part of the container material homogeneously dispersed throughout the container walls, or discretely sealed in multiple areas of the container providing zones of direct contact with the blood or blood products, or coated, deposited or attached to the inside walls of the container in direct contact with the blood or blood products.

[0023] Certain embodiments concern filters comprising any of the composition discussed herein. Some embodiments, concern a filter cartridge comprising any of the composition discussed herein. Some devices of the invention are blood filtration devices comprising a filter or filter cartridge comprising the any of the composition discussed herein.

[0024] In some embodiments the composition is contained in a filter and either the blood from the donor at the time of donation is passed through the filter before placement into a suitable blood container or the blood or blood products in the blood container pass through the filter during transfusion into the patient. For purposes of this invention, the term "sorb" is defined as "taking up and binding by absorption and adsorption".

[0025] The sorbents of the present invention have a skeletal density in the range of from 1.1 g/ml to 1.3 g/ml. Certain sorbents have a skeletal density that is substantially the same as the density of the blood or blood product. In other embodiments, the sorbent polymeric bead is for sorbing impurities from blood comprising the any of the composition described herein where the sorbent polymeric bead has a neutral or near-neutral buoyancy in the stored blood or blood products.

[0026] In some embodiments, as used herein, "substantially the same" means plus or minus 10% of the referenced value. As used herein, "near-neutral buoyancy" means that the sorbent has substantially the same density as the stored blood or blood product.

[0027] In certain embodiments, the methods of the invention use a seed polymerization method including seed of polymers based on 100% hetero atom monomer and non hetero atom monomers such that the combination can lead

to a neutrally buoyant system. Certain seed polymers are comprised of a mixture of hetero atom and non hetero atom monomer.

[0028] With some methods of the invention, the sorbent is in a suitable container to hold blood and in direct contact with blood and blood products but incapable of escaping from the container at a level that meets USP particulate as specified in IARC monograph 65. IARC (International Agency for Research on Cancer) Monographs identify environmental factors that can increase the risk of human cancer.

[0029] One advantage of the invention is that with the creation of neutrally buoyant, or near neutrally buoyant beads, due to a density similar to blood products, the beads remain naturally dispersed throughout blood or blood product, allowing substances in blood to be sorbed by the beads without the need, or with the reduced need, to mix or agitate the blood container.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030]

Figure 1 shows the skeletal densities of the polymers created vs the weight percent of 4-chlorostyrene for Commercial 63% and 80% Divinylbenzene. This proves that higher weight percentages of 4-chlorostyrene yield greater skeletal densities of the final polymer. In the figure, down arrows (↓) represents a sinking bead, up arrow (↑) a floating bead and N is neutrally buoyant bead in Packed Red Blood Cells.

Figure 2 shows the distribution of neutrally buoyant beads in packed red blood cells.

Figure 3 displays the relationship between pore volume of the polymers created to the percent commercial Divinylbenzene and weight percent of 4-chlorostyrene used in the organic phase. This is used to illustrate that 80% divinylbenzene yielded higher pore volumes than 63% divinylbenzene with equal amounts of 4-chlorostyrene present.

Figure 4 is a graph which shows pore volume as a function of pore diameter based on mercury intrusion. A high pore volume at a given pore diameter means there are many pores of that size; a lower pore volume at a given pore diameter means few pores of the given size.

Figure 5 is a graph which shows pore volume as a function of pore diameter based on nitrogen desorption. A high pore volume at a given pore diameter means there are many pores of that size; a lower pore volume at a given pore diameter means few pores of the given size.

Figure 6 illustrates that in order to create neutrally buoyant polymer beads, as the pore volume of the polymer increases, the skeletal density of the polymer must also increase.

Figure 7 shows the variation in the sorption of biomolecules for the three different sized polymers which were created.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0031] As required, detailed embodiments of the present invention are disclosed herein; it is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various forms.

Example 1: Overall Synthetic Approach

[0032] In the pursuit of neutrally buoyant beads, early testing revealed that divinylbenzene based polymers, porous and solid beads, floated on packed red blood cells. Red blood cells (alone) have a density of 1.125 g/mL, while some of our divinylbenzene porous polymers have skeletal densities of 1.082 g/mL. In practice, bags of packed red blood cells contain more than the cells alone, including substances such as preservative (e.g. SAG), and residual plasma that can cause the density of packed red blood cells to vary from one bag to another. Plasma has a density of 1.025 g/mL. During our studies we found hematocrit values between 40% to 60%. Interestingly, poly 4-chlorostyrene has a density of 1.55 g/mL. Therefore, it was envisioned that at specific ratios, copolymerization of divinylbenzene and 4-chlorostyrene would yield a range of neutrally buoyant bead in packed red blood cells. Increasing amounts of 4-chlorostyrene was reacted with commercial 63% divinylbenzene as shown in **Figure 1** to yield a medium pore type polymer with varying densities. Structural density increased as predicted (as measured by a helium pycnometer). In **Figure 1**, the down arrows (↓) represents a sinking bead, up arrow (↑) a floating bead and N is neutrally buoyant bead. Commercial 63% divinylbenzene yielded a neutrally buoyant bead at ~1.13 g/mL of skeletal density. **Figure 1** also incorporates commercial 80% divinylbenzene in decreasing skeletal density sequence to yield a neutrally buoyant bead. As displayed in **Figure 3**, this sequence resulted in larger pore volumes, compared to 63% divinylbenzene, and was developed further. Two additional neutrally buoyant polymer types targeting different pore ranges using 80% divinylbenzene were synthesized via the same methodology. Examples 2, 3, and 4 are the three neutrally buoyant polymer types developed. Typical examples of how neutrally buoyant beads distribute in packed red blood cells are shown in **Figure 2**.

[0033] Using these techniques, one skilled in the art can create beads with either a uniform density or a mixture of

beads that vary in density, allowing some or all of the beads to be neutrally buoyant and dispersed throughout or in a band within blood products (e.g. packed red blood cells, platelets, etc.) in packed red blood cells of varying densities. Neutral buoyancy, or isodensity, or near neutral buoyancy allows beads to disperse throughout the blood or blood product with fewer beads that settle at the bottom of the blood or float at the surface of the blood. This is intended to enable the beads to efficiently remove BAMs without needing to agitate or mix the blood container. In some embodiments, a mixture of beads ranging in apparent density through modification of pore volume, pore density or combination thereof can provide a dispersion or bands of beads throughout the bag.

Examples 2-4: Sorbent Synthesis

[0034] Three porous polymeric sorbents are characterized for their pore structures and their syntheses are described in example 2, 3, and 4. The structural characterization is given in Example 5, 6 and 7. The polymers synthesized in these steps would then be placed into a suitable blood container

[0035] The synthesis process consists of (1) preparing the aqueous phase, (2) preparing the organic phase, (3) carrying out the suspension polymerization, (4) purifying the resulting porous polymeric adsorbent product (work-up), and (5) addition of a hemocompatible coating.

[0036] Reactor Setup. A 0.5L kettle reactor was fitted with an over-head stirrer with a multi-level stirrer blade, a water cooled condenser, a thermocouple, and a bubbler. A gasket was installed between the top lid and bottom kettle. All unused ports were capped with the appropriate plug. Temperature was controlled with a heating mantle which was regulated by a temperature controller fitted with the above-mentioned thermocouple.

[0037] Polymerization. Polyvinyl alcohol ("PVA") was dispersed in one half of the water charge at room temperature (RT) and then heated to 70°C. The remaining salts: MSP, DSP, TSP, & Sodium Nitrite (see Table 1) were then dissolved in the remainder of the water charge. The PVA solution and salts solution were each added to the reactor and heated to the desired reaction temperature (see Table 1) with stirring. The pre-mixed organic phase, including the initiator, was poured into the reactor onto the aqueous phase with the stirring speed set at the revolutions per minute ("rpm") for formation of appropriate droplet. Once the temperature reached the set-point, the reaction timer was set for 16 hours and started and the reaction was allowed to proceed.

[0038] Work-up. Final solvent level was marked on the reactor. After cooling, the solvent was siphoned out to the bead level. The reactor was filled to the mark with (RT) water and heated to between 50 °C to 70 °C and stirred for 30 minutes. Then it was allowed to settle for 3 to 5 minutes and the liquid was siphoned out to bead level. The beads were washed five times in this manner. The reactor was then filled to the mark with RT methanol, if applicable (see Table 1), and stirred at RT for 5 minutes. Beads were allowed to settle for 3 to 5 minutes. Beads were washed 3 times in this manner. The polymer was steam stripped for 8 hours. After the steam strip was completed, the polymer was rewet in isopropyl alcohol and then sieved with purified water to the desired particle size. The polymer was then dried in an oven at 100 °C.

[0039] This process resulted in a clean, dry adsorbent in the form of spherical, porous polymer beads.

[0040] The polymer could then be modified for greater hemocompatibility via the procedure from US Patent No. 6,114,466.

Table 1. Synthesis conditions for neutrally buoyant polymers

	Example 2 SFA-102-155	Example 3 RJR-100-112	Example 4 RJR-100-110
Run Conditions			
Kettle Size	0.5	0.5	0.5
Reaction Temperature (°C)	80	87	87
Aqueous Phase Charges			
Item	Charge, g	Charge, g	Charge, g
Ultrapure Water	231.26	231.26	231.26
Polyvinyl Alcohol (PVA)	0.68	0.68	0.68
Monosodium Phosphate (MSP)	0.71	0.71	0.71
Disodium Phosphate (DSP)	2.36	2.36	2.36
Trisodium Phosphate (TSP)	1.47	1.47	1.47
Sodium Nitrite	0.01	0.01	0.01
Total	236.49	236.49	236.49

(continued)

Organic Phase Charges

	Item	Charge, g	Charge, g	Charge, g
5	Divinylbenzene (DVB)(80%)	66.4	64.97	101.57
	4-Chlorostyrene	23.1	23.1	35.81
	Toluene	55.78	0.00	0.00
	Isooctane	64.07	0.00	0.00
	Cyclohexanol	0.00	151.03	102.93
10	Benzoyl Peroxide (BPO)(97%)	0.90	0.90	0.90
	Total, w/o BPO	209.35	239.10	240.31

Work-Up

15	Methanol Washes	N/A	3	3
----	-----------------	-----	---	---

Example 5: Pore Structure Characterization

[0041] The pore structures of the sorbent polymers were analyzed with both a Micromeritics AutoPore IV 9500 V1.09 Mercury Penetrometer (Hg Intrusion instrument) or a Micromeritics ASAP 2010 instrument (N₂ Desorption) to show the existence of large pores and small pores. The results are provided in **Figures 4 and 5** where the pore volume is plotted as a function of the pore diameter. Varying pore structure allows for polymers to sorb a range of different harmful byproducts in blood as shown in **Figure 7**.

Examples 6 and 7: Density Characterization

[0042] For each polymer made, the density was determined using two different techniques. The first technique used was helium pycnometry. A Micromeritics AccuPyc 1330 for 1 cm³ samples, was used to determine the skeletal density (density of the polymer backbone) of each polymer.

[0043] A second technique was also needed because neutral buoyancy is defined by the Archimedes principal where an object is buoyed up by a force equal to the weight of the liquid displaced by the object. In the case of a porous polymer bead this represents a unique situation where the composite porous bead density is a function of the skeletal density and medium occupied in the bead pores.

[0044] The relationship can be expressed as follows in equation 1:

$$\text{Equation 1: } \rho_{\text{bead apparent}} = (\% \text{ volume non porous}) * \rho_{\text{skeletal}} + (\% \text{ volume porous}) * \rho_{\text{suspension media}}$$

[0045] In the case of a neutrally buoyant porous polymer:

$$\text{Equation 2: } \rho_{\text{bead apparent}} = \rho_{\text{suspension media}} \text{ (assumes no appreciable sorption of solutes)}$$

[0046] The second technique, which determined the apparent density, was a simple lab test where the polymer was placed in blood so that neutral buoyancy could be determined visually. **Figure 2**, which is the end result of this second technique, shows that the beads are suspended in the middle of the sample of blood so they are determined to be neutrally buoyant. The polymers RJR 100-110, SFA 102-155, and RJR 100-112 were all neutrally buoyant in Packed RBC's; therefore, the apparent density was nearly equivalent to the Packed RBC's. It should be noted, that increases in pore volume required increases in skeletal density to offset potential reduction in apparent density due to lower density preservatives (SAG for example) and plasma entering the pores. This is demonstrated in **Figure 6**.

Example 8: Sorption of Biomolecules

[0047] Non-competitive Equilibrium Isotherms were run on RJR 100-110, SFA 102-155, and RJR 100-112 in buffer solution to evaluate the sorption capacity for Cytochrome c (Cyt C, 12 kDa), Human Serum Albumin (HSA, 67 kDa) and Immunoglobulin G (IgG, 150 kDa). Cyt C, HSA, and IgG are acting as molecular weight surrogates for the Biologically Active Molecules (BAM)s. Each was individually tested and all values were measured by UV/V is Absorbance and reported as mg of protein sorbed/g of dry polymer.

Claims

1. A method of treating stored blood and blood products maximizing shelf life and/or minimizing a transfusion related complication by removing undesirable molecules in the blood and blood products milieu through use of a sorbent, wherein the sorbent has a skeletal density in the range of from 1.1 g/ml to 1.3 g/ml, and wherein the sorbent is a biocompatible copolymer of divinylbenzene and 4-chlorostyrene.

2. The method of claim 1 wherein:-

- a) said transfusion related complication is a non-hemolytic transfusion reaction; or
- b) said transfusion related complication is a non-hemolytic transfusion reaction selected from fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and an allergic reaction.

3. The methods of claim 1 or 2, wherein:-

- a) said undesirable molecules are biologically active molecules (BAMs), biological response modifiers (BRMs), products of hemolysis, products of membrane or cellular degradation, toxins, drugs, antibodies, prions and similar molecules found in stored blood and blood products; or
- b) said undesirable molecules are biologically active molecules or biological response modifiers and are removed from said blood or blood products; or
- c) said undesirable molecules are biologically active molecules or biological response modifiers selected from inflammatory mediators and stimulants and are removed from said blood or blood products; or
- d) said undesirable molecules are biologically active molecules or biological response modifiers selected from inflammatory mediators and stimulants selected from cytokines, nitric oxide, thromboxanes, leukotrienes, platelet-activating factor, prostaglandins, glycoproteins, kinins, kininogens, complement factors, cell-adhesion molecules, superantigens, monokines, chemokines, interferons, free radicals, proteases, arachidonic acid metabolites, prostacyclins, beta endorphins, myocardial depressant factors, anandamide, 2-arachidonylglycerol, tetrahydrobiopterin, serotonin, histamine, bradykinin, soluble CD40 ligand, bioactive lipids, oxidized lipids, hemoglobin, red cell particulates, membrane or cellular components, growth factors, glycoproteins, prions, toxins, endotoxins, drugs, vasoactive substances, foreign antigens, and antibodies and are removed from said blood or blood products.

4. The method of claim 2 where undesirable molecules are antibodies.

5. The method of claim 1, wherein said polymer is hemocompatible.

6. The method of claim 1 or 5,

- a) wherein said biocompatible or hemocompatible polymer comprises particles having a diameter in the range for 0.1 micron meters to 2 centimeters; or
- b) wherein said biocompatible or hemocompatible polymer comprises particles having a diameter in the range for 0.1 micron meters to 2 centimeters and wherein said biocompatible polymer is supplied as a slurry, or suspension, or dry powder or other dry particulate capable of being wetted; or
- c) wherein said polymer comprising particles having a diameter in the range for 0.1 micron meters to 2 centimeters, is porous, and has a pore structure that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry polymer.

7. The method of any of claims 1 to 6,

- a) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 100 Å to 1,000 Å (pore diameter) of the sorbent is smaller than 3:1; or
- b) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 100 Å to 1,000 Å (pore diameter) of the sorbent is smaller than 3:1, and wherein the undesirable molecule is a toxin having a molecular weight that is equal to or less than 50,000 Daltons; or

c) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1; or

d) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1, and wherein the undesirable molecule is a toxin having a molecular weight in the range of from 100 Daltons to 450,000 Daltons; or.

e) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 10,000 Å to 40,000 Å (pore diameter) of the sorbent is smaller than 3:1; or

f) wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 10,000 Å to 40,000 Å (pore diameter) of the sorbent is smaller than 3:1, and wherein the undesirable molecule is a toxin having a molecular weight that is equal to or less than 1,000,000 Daltons.

8. The method of claim 1, wherein said sorbent is produced using at least one of suspension, seed, dispersion, precipitation, multistage, membrane/microchannel emulsification and microfluidic polymerizations.

9. The method of claim 1, wherein said divinylbenzene is selected from 63% divinylbenzene and 80% divinylbenzene.

10. The method of claim 1, wherein the use of an organic solvent and or polymeric porogen as the porogen or pore-former, and the resulting phase separation induced during polymerization yield porous polymers.

11. The method of claim 1, wherein said sorbent comprises a hemocompatible surface comprises hydroxyethyl cellulose, hydroxypopyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylamino ethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly-(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), salts of poly(acrylic acid) or copolymers of mixtures thereof, wherein said hemocompatible surface is chemically bound to the cross-linked polymeric material.

12. The method of claim 1 or 5, wherein said polymer is modified with ligands that specifically or non-specifically bind reactive biomolecules.

13. The method of any one of claims 1-12,

a) wherein said sorbent is contained in a blood container with said blood or blood products; or

b) wherein said sorbent is contained in cartridge that may be used at time of collection as blood is placed in the bag for storage or at the point of use during transfusion; or

c) wherein said sorbent is in a suitable container to hold blood and in direct contact with blood and blood products but incapable of escaping from the container; or

d) wherein said sorbent is in a suitable container to hold blood and separated from the blood by a permeable membrane or barrier allowing fluid but not cells to interact with the polymer; or

e) wherein said sorbent is structurally an integral part of the container material homogeneously dispersed throughout the container walls, or discretely sealed in multiple areas of the container providing zones of direct contact with the blood or blood products, or coated, deposited or attached to the inside walls of the container in direct contact with the blood or blood products.

14. The method of claim 1, wherein the sorbent has a skeletal density that is substantially the same as the density of the blood or blood product.

15. A sorbent polymeric bead for sorbing impurities from blood comprising the composition defined in any of the claims 6 and 7.

16. The sorbent polymeric bead of claim 15, wherein the sorbent has a skeletal density that is substantially the same

as the density of the blood or blood product.

17. The method of claim 8, wherein said seed polymerization method including seed of polymers utilizes a combination of 100% hetero atom monomers and non-hetero atom monomers.

18. The method of claim 14 where said seed polymers are comprised of a mixture of hetero atom and non hetero atom monomer.

19. The method of claim 14, wherein said beads are placed in a container where, due to a density similar to blood products, said bead remain naturally dispersed throughout blood or blood product, allowing undesirable molecules in blood to be sorbed by the beads without the need to mix or agitate the container.

Patentansprüche

1. Verfahren zum Behandeln von aufbewahrtm Blut und Blutprodukten, das die Haltbarkeit maximiert und/oder eine transfusionsassoziierte Komplikation minimiert, indem unerwünschte Moleküle im Blut- und Blutproduktemilieu unter Verwendung eines Sorptionsmittels entfernt werden, wobei das Sorptionsmittel eine Reindichte im Bereich von 1,1 g/ml bis 1,3 g/ml aufweist und wobei das Sorptionsmittel ein biokompatibles Copolymer von Divinylbenzol und 4-Chlorstyrol ist.

2. Verfahren nach Anspruch 1, wobei:

- a) die transfusionsassoziierte Komplikation eine nichthämolytische Transfusionsreaktion ist; oder
- b) die transfusionsassoziierte Komplikation eine nichthämolytische Transfusionsreaktion ist, die ausgewählt ist aus Fieber, transfusionsassoziiierter akuter Lungeninsuffizienz (TRALI), transfusionsassoziiierter Dyspnoe (TAD) und einer allergischen Reaktion.

3. Verfahren nach Anspruch 1 oder 2, wobei:

- a) die unerwünschten Moleküle biologisch aktive Moleküle (BAM), biologische Regulationsmodulatoren (BRM), Hämolyseprodukte, Membran- oder Zellabbauprodukte, Toxine, Arzneistoffe, Antikörper, Prionen und ähnliche Moleküle sind, die in aufbewahrtm Blut und aufbewahrten Blutprodukten vorkommen; oder
- b) wobei die unerwünschten Moleküle biologisch aktive Moleküle oder biologische Regulationsmodulatoren sind und aus dem Blut oder den Blutprodukten entfernt werden; oder
- c) wobei die unerwünschten Moleküle biologisch aktive Moleküle oder biologische Regulationsmodulatoren sind, die ausgewählt sind aus Entzündungsmediatoren und - stimulatoren, und aus dem Blut oder den Blutprodukten entfernt werden; oder
- d) wobei die unerwünschten Moleküle biologisch aktive Moleküle oder biologische Regulationsmodulatoren sind, die ausgewählt sind aus Entzündungsmediatoren und - stimulatoren, die ausgewählt sind aus Cytokinen, Stickstoffmonoxid, Thromboxanen, Leukotrienen, plättchenaktivierendem Faktor, Prostaglandinen, Glykoproteinen, Kininen, Kininogenen, Komplementfaktoren, Zelladhäsionsmolekülen, Superantigenen, Monokinen, Chemokinen, Interferonen, freien Radikalen, Proteasen, Arachidonsäuremetaboliten, Prostacyclinen, Beta-Endorphinen, Myokard-Depressionsfaktoren, Anandimid, 2-Arachidonylglycerin, Tetrahydrobiopterin, Serotonin, Histamin, Bradykinin, löslichen CD40-Liganden, bioaktiven Lipiden, oxidierten Lipiden, Hämoglobin, roten Blutkörperchenteilen, Membran- oder Zellkomponenten, Wachstumsfaktoren, Glykoproteinen, Prionen, Toxinen, Endotoxinen, Arzneistoffen, vasoaktiven Substanzen, fremden Antigenen sowie Antikörpern, und aus dem Blut oder den Blutprodukten entfernt werden.

4. Verfahren nach Anspruch 2, wobei die unerwünschten Moleküle Antikörper sind.

5. Verfahren nach Anspruch 1, wobei das Polymer hämokompatibel ist.

6. Verfahren nach Anspruch 1 oder 5,

- a) wobei das biokompatible oder hämokompatible Polymer Partikel mit einem Durchmesser im Bereich von 0,1 Mikrometern bis 2 Zentimetern umfasst; oder
- b) wobei das biokompatible oder hämokompatible Polymer Partikel mit einem Durchmesser im Bereich von 0,1

Mikrometern bis 2 Zentimetern umfasst und wobei das biokompatible Polymer als Aufschlämmung oder Suspension oder Trockenpulver oder sonstige trockene Teilchen zugeführt wird, die in der Lage sind, befeuchtet zu werden; oder

c) wobei das Polymer Partikel mit einem Durchmesser im Bereich von 0,1 Mikrometern bis 2 Zentimetern umfasst, porös ist und eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Polymer ist.

7. Verfahren nach einem der Ansprüche 1 bis 6,

a) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 100 Å und 1.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 3:1 ist; oder

b) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 100 Å und 1.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 3:1 ist und wobei das unerwünschte Molekül ein Toxin mit einem Molekulargewicht ist, das gleich oder kleiner als 50.000 Dalton ist; oder

c) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 1.000 Å und 10.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 2:1 ist; oder

d) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 1.000 Å und 10.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 2:1 ist und wobei das unerwünschte Molekül ein Toxin mit einem Molekulargewicht im Bereich von 100 Dalton bis 450.000 Dalton ist; oder

e) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 10.000 Å und 40.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 3:1 ist; oder

f) wobei das Sorptionsmittel eine solche Porenstruktur aufweist, dass das Gesamtvolumen von Porengrößen im Bereich von 50 Å bis 40.000 Å größer als 0,5 cc/g bis 5,0 cc/g trockenes Sorptionsmittel ist; wobei das Verhältnis von Porenvolumen zwischen 50 Å und 40.000 Å (Porendurchmesser) zu Porenvolumen zwischen 10.000 Å und 40.000 Å (Porendurchmesser) des Sorptionsmittels kleiner als 3:1 ist und wobei das unerwünschte Molekül ein Toxin mit einem Molekulargewicht ist, das gleich oder kleiner als 1.000.000 Dalton ist.

8. Verfahren nach Anspruch 1, wobei das Sorptionsmittel unter Verwendung von mindestens einem von Suspensions-Saat-, Dispersions-, Fällungs-, mehrstufiger, Membran/Mikrokanal-Emulsions- und Mikrofluid-Polymerisation hergestellt wird.

9. Verfahren nach Anspruch 1, wobei das Divinylbenzol ausgewählt ist aus 63%igem Divinylbenzol und 80%igem Divinylbenzol.

10. Verfahren nach Anspruch 1, wobei die Verwendung eines organischen Lösungsmittels und/oder polymeren Porengens als Porenogen oder Porenbildner und die resultierende Phasentrennung, die während der Polymerisation induziert wird, poröse Polymere ergeben.

11. Verfahren nach Anspruch 1, wobei das Sorptionsmittel eine hämokompatible Oberfläche umfasst, die Hydroxyethylcellulose, Hydroxypropylcellulose, Poly(hydroxyethylmethacrylat), Poly(hydroxyethylacrylat), Poly(hydroxypropylmethacrylat), Poly(hydroxypropylacrylat), Poly(dimethylaminoethylmethacrylat), Poly(dimethylaminoethylacrylat), Poly(diethylaminoethylmethacrylat), Poly(diethylaminoethylacrylat), Poly(vinylalkohol), Poly(N-vinylpyrrolidinon), Salze der Poly(methacrylsäure), Salze der Poly(acrylsäure) oder Copolymere oder Mischungen davon umfasst, wobei die hämokompatible Oberfläche chemisch an das vernetzte polymere Material gebunden ist.

12. Verfahren nach Anspruch 1 oder 5, wobei das Polymer mit Liganden, die reaktionsfähige Biomoleküle spezifisch oder unspezifisch binden, modifiziert ist.

13. Verfahren nach einem der Ansprüche 1-12,

- a) wobei das Sorptionsmittel in einem Blutbehältnis mit dem Blut oder den Blutprodukten enthalten ist; oder
 b) wobei das Sorptionsmittel in einer Kartusche enthalten ist, die zur Zeit der Entnahme, wenn Blut im Beutel zur Aufbewahrung platziert wird, oder zum Zeitpunkt der Verwendung während einer Transfusion verwendet werden kann; oder
 c) wobei das Sorptionsmittel in einem Behältnis vorliegt, das sich dazu eignet, Blut aufzunehmen, und in direktem Kontakt mit Blut und Blutprodukten steht, jedoch aus dem Behältnis nicht entweichen kann; oder
 d) wobei das Sorptionsmittel in einem Behältnis vorliegt, das sich dazu eignet, Blut aufzunehmen, und von dem Blut durch eine permeable Membran oder Barriere getrennt ist, die es Flüssigkeiten, jedoch nicht Zellen, gestattet, mit dem Polymer zu interagieren; oder
 e) wobei das Sorptionsmittel strukturell ein integraler Bestandteil des Behältnismaterials ist, der homogen über die Behältniswände hinweg dispergiert ist, oder separat in mehreren Bereichen des Behältnisses abgeschlossen ist, wodurch Zonen von direktem Kontakt mit dem Blut oder den Blutprodukten bereitgestellt werden, oder auf die Innenwände des Behältnisses in direktem Kontakt mit dem Blut oder den Blutprodukten aufgetragen, darauf abgeschieden oder daran befestigt ist.

14. Verfahren nach Anspruch 1, wobei das Sorptionsmittel eine Reindichte aufweist, die im Wesentlichen gleich der Dichte des Bluts oder Blutprodukts ist.

15. Polymeres Sorptionsmittelkugelchen zum Sorbieren von Verunreinigungen aus Blut, umfassend die in einem der Ansprüche 6 und 7 definierte Zusammensetzung.

16. Polymeres Sorptionsmittelkugelchen nach Anspruch 15, wobei das Sorptionsmittel eine Reindichte aufweist, die im Wesentlichen gleich der Dichte des Bluts oder Blutprodukts ist.

17. Verfahren nach Anspruch 8, wobei das Saatpolymerisationsverfahren, das eine Saat von Polymeren beinhaltet, eine Kombination aus 100%igen Heteroatommonomeren und Nichtheteroatommonomeren einsetzt.

18. Verfahren nach Anspruch 14 wobei die Saatpolymere aus einer Mischung von Heteroatom- und Nichtheteroatommonomer bestehen.

19. Verfahren nach Anspruch 14, wobei die Kugelchen in einem Behältnis platziert werden, in dem, aufgrund einer Dichte ähnlich jener von Blutprodukten, die Kugelchen natürlich im Blut oder Blutprodukt dispergiert bleiben, was es unerwünschten Molekülen im Blut gestattet, durch die Kugelchen sorbiert zu werden, ohne dass die Notwendigkeit besteht, das Behältnis zu mischen oder zu bewegen.

Revendications

1. Procédé de traitement de sang et de produits sanguins conservés, maximisant la durée de conservation et/ou minimisant une complication liée à la transfusion en éliminant des molécules indésirables dans le milieu constitué du sang et des produits sanguins par utilisation d'un sorbant, dans lequel le sorbant a une densité squelettique de 1,1 g/ml à 1,3 g/ml, et dans lequel le sorbant est un copolymère biocompatible de divinylbenzène et de 4-chloros-tyrène.

2. Procédé selon la revendication 1, dans lequel :

- a) ladite complication liée à la transfusion est une réaction transfusionnelle non hémolytique ; ou
 b) ladite complication liée à la transfusion est une réaction transfusionnelle non hémolytique sélectionnée parmi une fièvre, un œdème pulmonaire lésionnel aigu post-transfusionnel (TRALI), une dyspnée associée à la transfusion (DAT) et une réaction allergique.

3. Procédé selon la revendication 1 ou 2, dans lequel :

- a) lesdites molécules indésirables sont des molécules biologiquement actives (MBA), des modificateurs de réponse biologique (MRB), des produits d'hémolyse, des produits de dégradation membranaire ou cellulaire, des toxines, des médicaments, des anticorps, des prions et des molécules similaires que l'on trouve dans le

sang et les produits sanguins conservés ; ou

b) lesdites molécules indésirables sont des molécules biologiquement actives ou des modificateurs de réponse biologique et sont éliminées dudit sang ou desdits produits sanguins ; ou

5 c) lesdites molécules indésirables sont des molécules biologiquement actives ou des modificateurs de réponse biologique sélectionnés parmi des médiateurs et des stimulateurs inflammatoires et sont éliminées dudit sang ou desdits produits sanguins ; ou

10 d) lesdites molécules indésirables sont des molécules biologiquement actives ou des modificateurs de réponse biologique sélectionnés parmi des médiateurs et des stimulateurs inflammatoires sélectionnés parmi : cytokines, oxyde nitrique, thromboxanes, leucotriènes, facteur d'activation plaquettaire, prostaglandines, glycoprotéines, kinines, kininogènes, facteurs du complément, molécules d'adhésion cellulaire, superantigènes, monokines, chimiokines, interférons, radicaux libres, protéases, métabolites de l'acide arachidonique, prostacyclines, bêta-endorphines, facteurs de dépression myocardique, anandimide, 2-arachadonylglycérol, tétrahydrobioptérine, sérotonine, histamine, bradykinine, ligand de CD40 soluble, lipides bioactifs, lipides oxydés, hémoglobine, particules d'érythrocytes, composants membranaires ou cellulaires, facteurs de croissance, glycoprotéines, prions, toxines, endotoxines, médicaments, substances vasoactives, antigènes étrangers et anticorps, et sont éliminées dudit sang ou desdits produits sanguins.

4. Procédé selon la revendication 2, dans lequel les molécules indésirables sont des anticorps.

20 5. Procédé selon la revendication 1, dans lequel ledit polymère est hémocompatible.

6. Procédé selon la revendication 1 ou 5,

25 a) dans lequel ledit polymère biocompatible ou hémocompatible comprend des particules ayant un diamètre de 0,1 micromètre à 2 centimètres ; ou

b) dans lequel ledit polymère biocompatible ou hémocompatible comprend des particules ayant un diamètre de 0,1 micromètre à 2 centimètres et dans lequel ledit polymère biocompatible est fourni sous la forme d'une pâte liquide, ou d'une suspension, ou d'une poudre sèche, ou d'une autre matière particulaire sèche capable d'être mouillée ; ou

30 c) dans lequel ledit polymère comprenant des particules ayant un diamètre de 0,1 micromètre à 2 centimètres, est poreux, et a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de polymère sec.

7. Procédé selon l'une quelconque des revendications 1 à 6,

35 a) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 100 Å à 1 000 Å (diamètre des pores) du sorbant est inférieur à 3:1 ; ou

40 b) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 100 Å à 1 000 Å (diamètre des pores) du sorbant est inférieur à 3:1, et dans lequel la molécule indésirable est une toxine ayant une masse moléculaire qui est égale ou inférieure à 50 000 daltons ; ou

45 c) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 1 000 Å à 10 000 Å (diamètre des pores) du sorbant est inférieur à 2:1 ; ou

50 d) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 1 000 Å à 10 000 Å (diamètre des pores) du sorbant est inférieur à 2:1, et dans lequel la molécule indésirable est une toxine ayant une masse moléculaire de 100 daltons à 450 000 daltons ; ou

55 e) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 10 000 Å à 40 000 Å (diamètre des pores) du sorbant est inférieur à 3:1 ; ou

f) dans lequel le sorbant a une structure de pores telle que le volume total des pores ayant une taille de 50 Å

à 40 000 Å est supérieur à 0,5 cc/g à 5,0 cc/g de sorbant sec ; dans lequel le rapport du volume des pores de 50 Å à 40 000 Å (diamètre des pores) contre le volume des pores de 10 000 Å à 40 000 Å (diamètre des pores) du sorbant est inférieur à 3:1, et dans lequel la molécule indésirable est une toxine ayant une masse moléculaire qui est égale ou inférieure à 1 000 000 daltons.

- 5 8. Procédé selon la revendication 1, dans lequel ledit sorbant est produit en utilisant au moins l'une de polymérisations en suspension, avec nucléation, en dispersion, par précipitation, en plusieurs étapes, en émulsion dans un réacteur à membrane/microcanaux, et microfluidique.
- 10 9. Procédé selon la revendication 1, dans lequel ledit divinylbenzène est sélectionné parmi 63 % de divinylbenzène et 80 % de divinylbenzène.
- 15 10. Procédé selon la revendication 1, dans lequel l'utilisation d'un solvant organique et/ou d'un porogène polymère comme porogène ou agent de formation de pores et la séparation de phase en résultant induite durant la polymérisation produisent des polymères poreux.
- 20 11. Procédé selon la revendication 1, dans lequel ledit sorbant comprend une surface hémocompatible comprenant hydroxyéthylcellulose, hydroxypropylcellulose, poly(méthacrylate d'hydroxyéthyle), poly(acrylate d'hydroxyéthyle), poly(méthacrylate d'hydroxypropyle), poly(acrylate d'hydroxypropyle), poly(méthacrylate de diméthylaminoéthyle), poly(acrylate de diméthylaminoéthyle), poly(méthacrylate de diéthylaminoéthyle), poly(acrylate de diéthylaminoéthyle), poly(alcool vinylique), poly(N-vinylpyrrolidinone), sels de poly(acide méthacrylique), sels de poly(acide acrylique), ou copolymères de mélanges de ceux-ci, ladite surface hémocompatible étant liée chimiquement au matériau polymère réticulé.
- 25 12. Procédé selon la revendication 1 ou 5, dans lequel ledit polymère est modifié avec des ligands qui se lient spécifiquement ou non spécifiquement à des biomolécules réactives.
- 30 13. Procédé selon l'une quelconque des revendications 1 à 12,
 - a) dans lequel ledit sorbant est contenu dans un contenant pour le sang avec ledit sang ou lesdits produits sanguins ; ou
 - b) dans lequel ledit sorbant est contenu dans une cartouche qui peut être utilisée au moment du prélèvement lorsque le sang est introduit dans la poche pour la conservation, ou au point d'utilisation durant la transfusion ; ou
 - 35 c) dans lequel ledit sorbant se trouve dans un contenant apte à contenir du sang et en contact direct avec le sang et les produits sanguins, mais incapable de s'échapper du contenant ; ou
 - d) dans lequel ledit sorbant se trouve dans un contenant apte à contenir du sang et est séparé du sang par une membrane ou une barrière perméable permettant au fluide, mais pas aux cellules, d'interagir avec le polymère ; ou
 - 40 e) dans lequel ledit sorbant fait structuralement partie intégrante du matériau du contenant, étant dispersé de façon homogène à travers les parois du contenant, ou est enfermé hermétiquement de façon discontinue dans de multiples régions du contenant formant des zones de contact direct avec le sang ou les produits sanguins, ou est enduit, déposé ou fixé aux parois intérieures du contenant en contact direct avec le sang ou les produits sanguins.
- 45 14. Procédé selon la revendication 1, dans lequel le sorbant a une densité squelettique qui est sensiblement identique à la densité du sang ou du produit sanguin.
- 50 15. Perle polymère sorbante destinée à la sorption d'impuretés à partir du sang, comprenant la composition définie dans l'une quelconque des revendications 6 et 7.
- 55 16. Perle polymère sorbante selon la revendication 15, dans laquelle le sorbant a une densité squelettique qui est sensiblement identique à la densité du sang ou du produit sanguin.
17. Procédé selon la revendication 8, dans lequel ledit procédé de polymérisation avec nucléation comprenant des germes polymères utilise une combinaison de monomères contenant 100 % d'hétéroatomes et de monomères ne contenant pas d'hétéroatomes.
18. Procédé selon la revendication 14, dans lequel lesdits germes polymères sont constitués d'un mélange de mono-

mères contenant des hétéroatomes et de monomères ne contenant pas d'hétéroatomes.

- 5 **19.** Procédé selon la revendication 14, dans lequel lesdites perles sont placées dans un contenant dans lequel, en raison d'une densité similaire aux produits sanguins, lesdites perles restent naturellement dispersées à travers le sang ou le produit sanguin, permettant aux molécules indésirables dans le sang d'être sorbées par les perles sans avoir besoin de mélanger ou d'agiter le contenant.

10

15

20

25

30

35

40

45

50

55




FIG. 1





FIG. 2








FIG. 3

**FIG. 4**

**FIG. 5**

**FIG. 6**

**FIG. 7**

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2012094565 A1 [0003]
- WO 2009158027 A1 [0003]
- US 2008119576 A1 [0003]
- DE 10157569 A1 [0003]
- US 6114466 A [0040]

Non-patent literature cited in the description

- **GOKMEN MT ; DU PREZ FE.** Porous polymer particles-A comprehensive guide to synthesis, characterization, functionalization and applications. *Prog Polym Sci*, 2012, vol. 37, 365-405 [0010]